Skip to main content
Top
Published in: Clinical Rheumatology 6/2016

01-06-2016 | Original Article

Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs

Authors: Masahiro Tada, Kentaro Inui, Yuko Sugioka, Kenji Mamoto, Tadashi Okano, Takuya Kinoshita, Noriaki Hidaka, Tatsuya Koike

Published in: Clinical Rheumatology | Issue 6/2016

Login to get access

Abstract

Biological disease-modifying antirheumatic drugs (bDMARDs) have become more popular for treating rheumatoid arthritis (RA). Whether or not bDMARDs increase the postoperative risk of surgical site infection (SSI) has remained controversial. We aimed to clarify the effects of bDMARDs on the outcomes of elective orthopedic surgery. We used multivariate logistic regression analysis to analyze risk factors for SSI and delayed wound healing among 227 patients with RA (mean age, 65.0 years; disease duration, 16.9 years) after 332 elective orthopedic surgeries. We also attempted to evaluate the effects of individual medications on infection. Rates of bDMARD and conventional synthetic DMARD (csDMARD) administration were 30.4 and 91.0 %, respectively. Risk factors for SSI were advanced age (odds ratio [OR], 1.11; P = 0.045), prolonged surgery (OR, 1.02; P = 0.03), and preoperative white blood cell count >10,000/μL (OR, 3.66; P = 0.003). Those for delayed wound healing were advanced age (OR, 1.16; P = 0.001), prolonged surgery (OR, 1.02; P = 0.007), preoperative white blood cell count >10,000/μL (OR, 4.56; P = 0.02), and foot surgery (OR, 6.60; P = 0.001). Risk factors for SSI and medications did not significantly differ. No DMARDs were risk factors for any outcome examined. Biological DMARDs were not risk factors for postoperative SSI. Foot surgery was a risk factor for delayed wound healing.
Literature
1.
go back to reference Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 58(2 Suppl):S126–S135. doi:10.1002/art.23364 PubMed Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 58(2 Suppl):S126–S135. doi:10.​1002/​art.​23364 PubMed
2.
go back to reference Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162–1167. doi:10.1136/ard.2006.068064 CrossRefPubMedPubMedCentral Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162–1167. doi:10.​1136/​ard.​2006.​068064 CrossRefPubMedPubMedCentral
3.
go back to reference Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096–1103. doi:10.1136/ard.2007.080002 CrossRefPubMedPubMedCentral Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096–1103. doi:10.​1136/​ard.​2007.​080002 CrossRefPubMedPubMedCentral
4.
go back to reference van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, Pangan AL (2010) Disease activity, physical function, and radiographic progression after long-term therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 37(11):2237–2246. doi:10.3899/jrheum.100208 CrossRefPubMed van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, Pangan AL (2010) Disease activity, physical function, and radiographic progression after long-term therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 37(11):2237–2246. doi:10.​3899/​jrheum.​100208 CrossRefPubMed
5.
go back to reference van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54(4):1063–1074. doi:10.1002/art.21655 CrossRefPubMed van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54(4):1063–1074. doi:10.​1002/​art.​21655 CrossRefPubMed
6.
go back to reference Fevang BT, Lie SA, Havelin LI, Engesaeter LB, Furnes O (2007) Reduction in orthopedic surgery among patients with chronic inflammatory joint disease in Norway, 1994–2004. Arthritis Rheum 57(3):529–532. doi:10.1002/art.22628 CrossRefPubMed Fevang BT, Lie SA, Havelin LI, Engesaeter LB, Furnes O (2007) Reduction in orthopedic surgery among patients with chronic inflammatory joint disease in Norway, 1994–2004. Arthritis Rheum 57(3):529–532. doi:10.​1002/​art.​22628 CrossRefPubMed
7.
go back to reference Momohara S, Tanaka S, Nakamura H, Mibe J, Iwamoto T, Ikari K, Nishino J, Kadono Y, Yasui T, Takahashi K, Takenouchi K, Hashizume K, Nakahara R, Kubota A, Nakamura T, Nishida K, Suguro T (2011) Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol 21(4):337–342. doi:10.1007/s10165-011-0426-7 CrossRefPubMed Momohara S, Tanaka S, Nakamura H, Mibe J, Iwamoto T, Ikari K, Nishino J, Kadono Y, Yasui T, Takahashi K, Takenouchi K, Hashizume K, Nakahara R, Kubota A, Nakamura T, Nishida K, Suguro T (2011) Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol 21(4):337–342. doi:10.​1007/​s10165-011-0426-7 CrossRefPubMed
9.
11.
go back to reference Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9):2287–2293. doi:10.1002/art.10524 CrossRefPubMed Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9):2287–2293. doi:10.​1002/​art.​10524 CrossRefPubMed
13.
go back to reference Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, Sakuma Y, Tokita A, Momohara S (2010) Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49(2):341–347. doi:10.1093/rheumatology/kep376 CrossRef Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, Sakuma Y, Tokita A, Momohara S (2010) Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49(2):341–347. doi:10.​1093/​rheumatology/​kep376 CrossRef
14.
go back to reference Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, Imamura H, Masuda I, Tokita A, Ikari K (2011) Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 21(5):469–475. doi:10.1007/s10165-011-0423-x CrossRefPubMed Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, Imamura H, Masuda I, Tokita A, Ikari K (2011) Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 21(5):469–475. doi:10.​1007/​s10165-011-0423-x CrossRefPubMed
15.
go back to reference Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25(5):331–335PubMed Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25(5):331–335PubMed
16.
go back to reference den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34(4):689–695 den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, de Waal-Malefijt M, van den Hoogen FH (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34(4):689–695
17.
18.
go back to reference Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60(3):214–217CrossRefPubMedPubMedCentral Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60(3):214–217CrossRefPubMedPubMedCentral
19.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed
21.
go back to reference Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19(4):351–357. doi:10.1007/s10165-009-0197-6 CrossRefPubMedPubMedCentral Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19(4):351–357. doi:10.​1007/​s10165-009-0197-6 CrossRefPubMedPubMedCentral
22.
go back to reference Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762–784. doi:10.1002/art.23721 CrossRefPubMed Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762–784. doi:10.​1002/​art.​23721 CrossRefPubMed
23.
go back to reference Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR (1999) Guideline for prevention of surgical site infection, Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20(4):250–278. doi:10.1086/501620, quiz 279–280CrossRefPubMed Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR (1999) Guideline for prevention of surgical site infection, Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20(4):250–278. doi:10.​1086/​501620, quiz 279–280CrossRefPubMed
24.
go back to reference Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, Kaneko A, Eto Y, Ishiguro N (2010) Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 29(5):495–500. doi:10.1007/s10067-009-1346-1 CrossRefPubMed Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, Kaneko A, Eto Y, Ishiguro N (2010) Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 29(5):495–500. doi:10.​1007/​s10067-009-1346-1 CrossRefPubMed
25.
26.
go back to reference Ito H, Kojima M, Nishida K, Matsushita I, Kojima T, Nakayama T, Endo H, Hirata S, Kaneko Y, Kawahito Y, Kishimoto M, Seto Y, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H (2015) Postoperative complications in patients with rheumatoid arthritis using a biological agent—a systematic review and meta-analysis. Mod Rheumatol 25(5):672–678. doi:10.3109/14397595.2015.1014302 CrossRefPubMed Ito H, Kojima M, Nishida K, Matsushita I, Kojima T, Nakayama T, Endo H, Hirata S, Kaneko Y, Kawahito Y, Kishimoto M, Seto Y, Kamatani N, Tsutani K, Igarashi A, Hasegawa M, Miyasaka N, Yamanaka H (2015) Postoperative complications in patients with rheumatoid arthritis using a biological agent—a systematic review and meta-analysis. Mod Rheumatol 25(5):672–678. doi:10.​3109/​14397595.​2015.​1014302 CrossRefPubMed
27.
go back to reference Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, Kondo N, Matsuno H, Wada T, Nonaka T, Kanbe K, Takagi H, Murasawa A, Matsubara T, Suguro T (2013) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 23(3):440–449. doi:10.1007/s10165-012-0683-0 CrossRefPubMed Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, Kondo N, Matsuno H, Wada T, Nonaka T, Kanbe K, Takagi H, Murasawa A, Matsubara T, Suguro T (2013) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 23(3):440–449. doi:10.​1007/​s10165-012-0683-0 CrossRefPubMed
28.
go back to reference Bibbo C, Anderson RB, Davis WH, Norton J (2003) The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients [corrected]. Foot Ankle Int 24(1):40–44PubMed Bibbo C, Anderson RB, Davis WH, Norton J (2003) The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients [corrected]. Foot Ankle Int 24(1):40–44PubMed
Metadata
Title
Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs
Authors
Masahiro Tada
Kentaro Inui
Yuko Sugioka
Kenji Mamoto
Tadashi Okano
Takuya Kinoshita
Noriaki Hidaka
Tatsuya Koike
Publication date
01-06-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3274-1

Other articles of this Issue 6/2016

Clinical Rheumatology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.